Diabetes Clinical Trials in Baltimore

Showing 661-661 of 661 trials

Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients

NCT00034255

The purpose of this study is to evaluate the safety and tolerability of single and multiple doses of intramuscular INGAP Peptide given for the first time in humans as a potential treatment for diabetes.

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2

GMP Endotherapeutics62 participantsStarted Dec 2001

San Diego, California, United States • Washington D.C., District of Columbia, United States • Durham, North Carolina, United States +1 more locations

PreviousPage 34 of 34

Single Dose and 34-Day Tolerance Study of INGAP Peptide in Insulin Deficient Patients

Diabetes Trials in Other Cities

Other Conditions in Baltimore